BSBE Seminar丨Dr. Cheng ZHANG from Amgen Inc.
Over the past decade, programmable Cas9 nucleases have revolutionized basic research and clinical applications. However, compared to Cas9-based DNA targeting tools, there is a lack of simple and effective tools for studying and manipulating RNA. The Type VI CRISPR-Cas13 system is currently the only known efficient programmable system exclusively targeting RNA. My research is focused on the type VI-D effector protein Cas13d, which is one of the smallest effectors in the Cas13 family, making it more advantageous for packaging into adeno-associated viruses. We utilized cryo-electron microscopy (cryo-EM), biochemical approaches, and hydrogen-deuterium exchange mass spectrometry to explore the conformational landscape of Cas13d during RNA processing, and utilized the structural insights to guide Cas13d protein engineering. Additionally, we established in vitro and cellular assays of using Cas13d to achieve mRNA knockdown, pre-mRNA splicing regulation, and RNA detection, providing proof-of-concept for future RNA-centric applications. Overall, our findings have the potential to significantly advance the field of transcriptome engineering and lead to more effective gene therapies.